PharmiWeb6d
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
STAT8h
Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance
It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.
The American Journal of Managed Care6d
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
Medscape3d
Thyroid Autoantibodies (TPOAb, TgAb and TRAb)
Alterations in thyroid gland function result from the action of stimulating or blocking autoantibodies on cell membrane receptors ... a result of a mother with antibodies due to AITD.
emjreviews.com2d
Vimentin Autoantibodies Linked to Novel CNS Disorder
Discover the identification of vimentin IgG autoantibodies in a novel autoimmune meningoencephalomyelitis, highlighting unique clinical features and implications for diagnosis and treatment.
Frontiers3d
Functional Roles of the Interaction of APP and Lipoprotein Receptors
The biological fates of the key initiator of Alzheimer’s disease (AD), the amyloid precursor protein (APP), and a family of lipoprotein receptors, the low-density lipoprotein (LDL) receptor-related ...